Company Name: Seres Therapeutics Inc.
Seres Therapeutics Inc. develops biological drugs using its microbiome therapeutics platform. The company’s products are designed to repair the function of a dysbiotic microbiome. The company’s initial focus is on developing products that are designed to treat dysbiosis in the colonic microbiome and its lead product candidate is designed to prevent recurrences of Clostridium difficile infection.
Ticker Symbol: MCRB (NASDAQ)
Company Website: www.serestherapeutics.com
Headquarters: Cambridge, MA